Selected research
Industry Research
Virus Like Particles Industry Research Report 2026
Market perspective
The global Virus Like Particles market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Virus Like Particles is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Virus Like Particles is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Virus Like Particles is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Virus Like Particles include Agilvax, Allergy Therapeutics, ANGANY Genetics, CPL Biologicals, Cytos Biotechnology, GeoVax Labs, Medicago, MedImmune and Novavax, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Virus Like Particles market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Virus Like Particles Market by Company
Agilvax
Allergy Therapeutics
ANGANY Genetics
CPL Biologicals
Cytos Biotechnology
GeoVax Labs
Medicago
MedImmune
Novavax
Serum Institute of India
TechnoVax
Xiamen Innovax Biotech
GlaxoSmithKline
Merck
Takeda
Virus Like Particles Segment by Type
Hepatitis B Virus
Adeno-Associated Virus
Hepatitis C Virus
HIV
Others
Virus Like Particles Segment by Application
Therapeutic and Imaging Agents
Mycoviruses
Vaccines
Virus Research
Others
Virus Like Particles Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Virus Like Particles market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Virus Like Particles and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Virus Like Particles.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Virus Like Particles manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Virus Like Particles by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Virus Like Particles in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Hepatitis B Virus
- Adeno-Associated Virus
- Hepatitis C Virus
- HIV
- Others
Applications
- Therapeutic and Imaging Agents
- Mycoviruses
- Vaccines
- Virus Research
- Others
Companies covered
- Agilvax
- Allergy Therapeutics
- ANGANY Genetics
- CPL Biologicals
- Cytos Biotechnology
- GeoVax Labs
- Medicago
- MedImmune
- Novavax
- Serum Institute of India
- TechnoVax
- Xiamen Innovax Biotech
- GlaxoSmithKline
- Merck
- Takeda
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Virus Like Particles Market Size (2021-2032)
- 2.2.2 Global Virus Like Particles Sales (2021-2032)
- 2.2.3 Global Virus Like Particles Market Average Price (2021-2032)
- 2.3 Virus Like Particles by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Hepatitis B Virus
- 2.3.3 Adeno-Associated Virus
- 2.3.4 Hepatitis C Virus
- 2.3.5 HIV
- 2.3.6 Others
- 2.4 Virus Like Particles by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Therapeutic and Imaging Agents
- 2.4.3 Mycoviruses
- 2.4.4 Vaccines
- 2.4.5 Virus Research
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Virus Like Particles Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Virus Like Particles Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Virus Like Particles Revenue of Manufacturers (2021-2026)
- 3.4 Global Virus Like Particles Average Price by Manufacturers (2021-2026)
- 3.5 Global Virus Like Particles Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Virus Like Particles, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Virus Like Particles, Product Type & Application
- 3.8 Global Manufacturers of Virus Like Particles, Established Date
- 3.9 Global Virus Like Particles Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Agilvax
- 4.1.1 Agilvax Company Information
- 4.1.2 Agilvax Business Overview
- 4.1.3 Agilvax Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Agilvax Virus Like Particles Product Portfolio
- 4.1.5 Agilvax Recent Developments
- 4.2 Allergy Therapeutics
- 4.2.1 Allergy Therapeutics Company Information
- 4.2.2 Allergy Therapeutics Business Overview
- 4.2.3 Allergy Therapeutics Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Allergy Therapeutics Virus Like Particles Product Portfolio
- 4.2.5 Allergy Therapeutics Recent Developments
- 4.3 ANGANY Genetics
- 4.3.1 ANGANY Genetics Company Information
- 4.3.2 ANGANY Genetics Business Overview
- 4.3.3 ANGANY Genetics Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 ANGANY Genetics Virus Like Particles Product Portfolio
- 4.3.5 ANGANY Genetics Recent Developments
- 4.4 CPL Biologicals
- 4.4.1 CPL Biologicals Company Information
- 4.4.2 CPL Biologicals Business Overview
- 4.4.3 CPL Biologicals Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 CPL Biologicals Virus Like Particles Product Portfolio
- 4.4.5 CPL Biologicals Recent Developments
- 4.5 Cytos Biotechnology
- 4.5.1 Cytos Biotechnology Company Information
- 4.5.2 Cytos Biotechnology Business Overview
- 4.5.3 Cytos Biotechnology Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Cytos Biotechnology Virus Like Particles Product Portfolio
- 4.5.5 Cytos Biotechnology Recent Developments
- 4.6 GeoVax Labs
- 4.6.1 GeoVax Labs Company Information
- 4.6.2 GeoVax Labs Business Overview
- 4.6.3 GeoVax Labs Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 GeoVax Labs Virus Like Particles Product Portfolio
- 4.6.5 GeoVax Labs Recent Developments
- 4.7 Medicago
- 4.7.1 Medicago Company Information
- 4.7.2 Medicago Business Overview
- 4.7.3 Medicago Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Medicago Virus Like Particles Product Portfolio
- 4.7.5 Medicago Recent Developments
- 4.8 MedImmune
- 4.8.1 MedImmune Company Information
- 4.8.2 MedImmune Business Overview
- 4.8.3 MedImmune Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 MedImmune Virus Like Particles Product Portfolio
- 4.8.5 MedImmune Recent Developments
- 4.9 Novavax
- 4.9.1 Novavax Company Information
- 4.9.2 Novavax Business Overview
- 4.9.3 Novavax Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Novavax Virus Like Particles Product Portfolio
- 4.9.5 Novavax Recent Developments
- 4.10 Serum Institute of India
- 4.10.1 Serum Institute of India Company Information
- 4.10.2 Serum Institute of India Business Overview
- 4.10.3 Serum Institute of India Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Serum Institute of India Virus Like Particles Product Portfolio
- 4.10.5 Serum Institute of India Recent Developments
- 4.11 TechnoVax
- 4.11.1 TechnoVax Company Information
- 4.11.2 TechnoVax Business Overview
- 4.11.3 TechnoVax Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 TechnoVax Virus Like Particles Product Portfolio
- 4.11.5 TechnoVax Recent Developments
- 4.12 Xiamen Innovax Biotech
- 4.12.1 Xiamen Innovax Biotech Company Information
- 4.12.2 Xiamen Innovax Biotech Business Overview
- 4.12.3 Xiamen Innovax Biotech Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Xiamen Innovax Biotech Virus Like Particles Product Portfolio
- 4.12.5 Xiamen Innovax Biotech Recent Developments
- 4.13 GlaxoSmithKline
- 4.13.1 GlaxoSmithKline Company Information
- 4.13.2 GlaxoSmithKline Business Overview
- 4.13.3 GlaxoSmithKline Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 GlaxoSmithKline Virus Like Particles Product Portfolio
- 4.13.5 GlaxoSmithKline Recent Developments
- 4.14 Merck
- 4.14.1 Merck Company Information
- 4.14.2 Merck Business Overview
- 4.14.3 Merck Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Merck Virus Like Particles Product Portfolio
- 4.14.5 Merck Recent Developments
- 4.15 Takeda
- 4.15.1 Takeda Company Information
- 4.15.2 Takeda Business Overview
- 4.15.3 Takeda Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Takeda Virus Like Particles Product Portfolio
- 4.15.5 Takeda Recent Developments
5 Global Virus Like Particles Market Scenario by Region
- 5.1 Global Virus Like Particles Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Virus Like Particles Sales by Region: 2021-2032
- 5.2.1 Global Virus Like Particles Sales by Region: 2021-2026
- 5.2.2 Global Virus Like Particles Sales by Region: 2027-2032
- 5.3 Global Virus Like Particles Revenue by Region: 2021-2032
- 5.3.1 Global Virus Like Particles Revenue by Region: 2021-2026
- 5.3.2 Global Virus Like Particles Revenue by Region: 2027-2032
- 5.4 North America Virus Like Particles Market Facts & Figures by Country
- 5.4.1 North America Virus Like Particles Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Virus Like Particles Sales by Country (2021-2032)
- 5.4.3 North America Virus Like Particles Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Virus Like Particles Market Facts & Figures by Country
- 5.5.1 Europe Virus Like Particles Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Virus Like Particles Sales by Country (2021-2032)
- 5.5.3 Europe Virus Like Particles Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Virus Like Particles Market Facts & Figures by Country
- 5.6.1 Asia Pacific Virus Like Particles Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Virus Like Particles Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Virus Like Particles Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Virus Like Particles Market Facts & Figures by Country
- 5.7.1 South America Virus Like Particles Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Virus Like Particles Sales by Country (2021-2032)
- 5.7.3 South America Virus Like Particles Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Virus Like Particles Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Virus Like Particles Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Virus Like Particles Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Virus Like Particles Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Virus Like Particles Sales by Type (2021-2032)
- 6.1.1 Global Virus Like Particles Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Virus Like Particles Sales Market Share by Type (2021-2032)
- 6.2 Global Virus Like Particles Revenue by Type (2021-2032)
- 6.2.1 Global Virus Like Particles Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Virus Like Particles Revenue Market Share by Type (2021-2032)
- 6.3 Global Virus Like Particles Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Virus Like Particles Sales by Application (2021-2032)
- 7.1.1 Global Virus Like Particles Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Virus Like Particles Sales Market Share by Application (2021-2032)
- 7.2 Global Virus Like Particles Revenue by Application (2021-2032)
- 7.2.1 Global Virus Like Particles Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Virus Like Particles Revenue Market Share by Application (2021-2032)
- 7.3 Global Virus Like Particles Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Virus Like Particles Value Chain Analysis
- 8.1.1 Virus Like Particles Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Virus Like Particles Production Mode & Process
- 8.2 Virus Like Particles Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Virus Like Particles Distributors
- 8.2.3 Virus Like Particles Customers
9 Global Virus Like Particles Analyzing Market Dynamics
- 9.1 Virus Like Particles Industry Trends
- 9.2 Virus Like Particles Industry Drivers
- 9.3 Virus Like Particles Industry Opportunities and Challenges
- 9.4 Virus Like Particles Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst